452911-09-0

Basic information

• Product Name: tert-butyl 1-(2-oxoethyl)cyclopropane-1-carboxylate
• Synonyms: tert-butyl 1-(2-oxoethyl)cyclopropane-1-carboxylate
• CAS NO: 452911-09-0
• Molecular Weight: 184.235
• Mol File: 452911-09-0.mol

Chemical Properties

• CAS DataBase Reference: tert-butyl 1-(2-oxoethyl)cyclopropane-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl 1-(2-oxoethyl)cyclopropane-1-carboxylate(452911-09-0)
• EPA Substance Registry System: tert-butyl 1-(2-oxoethyl)cyclopropane-1-carboxylate(452911-09-0)

Safety Data

• Hazardous Substances Data: 452911-09-0(Hazardous Substances Data)

Upstream product

• 87661-20-9 tert-butyl cyclopropanecarboxylate 
• 108546-98-1 1-allyl-cyclopropanecarboxylic acid tert-butyl ester 

Downstream Products

• 1101840-76-9 1-[2-(benzyl-tert-butoxycarbonylmethyl-amino)-ethyl]-cyclopropanecarboxylic acid tert-butyl ester 
• 1103501-89-8 (S)-6-aza-spiro[2.5]octan-4-ol hydrochloride 
• 1101840-77-0 6-benzyl-6-aza-spiro[2.5]octan-4-one hydrochloride 
• 1101840-81-6 (S)-6-Benzyl-6-aza-spiro[2.5]octan-4-ol 
• 1290048-29-1 4-[4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-5-oxo-[1,4]diazepane-1-carboxylic acid benzyl ester 
• 1290048-74-6 (S)-4-[(R,S)-3-Hydroxy-4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid benzyl ester 
• 1290049-74-9 (S)-4-[(E)-3-(3-Chloro-4-fluoro-phenyl)-acryloyl]-1-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-3-oxo-propyl]-3-methyl-piperazin-2-one 
• 1290049-14-7 (S)-4-[3-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-3-oxo-propyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid (3,4-dichloro-phenyl)-amide 
• 1290050-56-4 (S)-4-[(R,S)-3-hydroxy-4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-2-methyl-3-oxo-piperazine-1-carboxylic acid (3-chloro-4-trifluoromethyl-phenyl)-amide 
• 1290050-27-9 4-[4-((S)-4-hydroxy-6-aza-spiro[2.5]oct-6-yl)-4-oxo-butyl]-5-oxo-[1,4]diazepane-1-carboxylic acid (3-chloro-phenyl)-amide 
• 1103501-90-1 (S)-6-aza-spiro[2.5]octan-4-ol 

Relevant articles and documents

CALCIUM CHANNEL INHIBITORS

The present disclosure describes carbamate analogs of mibefradil, as well as their compositions and methods of use. The compounds block the activity of one or more isoforms of voltage-gated calcium channels and are useful in the treatment of diseases incl

OXO-HETEROCYCLICALLY SUBSTITUTED ALKYL CARBOXYLIC ACIDS AND USE THEREOF

The present application relates to novel alkylcarboxylic acids having an oxo-substituted azaheterocyclic partial structure, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel bicyclic compounds of formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9, and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor may be used, for example, in the prevention and/or treatment of inflammatory diseases, particularly peripheral arterial occlusive diseases or atherothrombosis.

DIAZEPAM DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTORS

The invention is concerned with novel bicyclic compounds of Formula (I), wherein n, m, p, A, L, R1, R2, R3, R4, R5, R6, R7, R7, R8, R9 and R10 are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I): wherein A, X, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and may be used as medicaments.

NOVEL HETEROCYCLYL COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y1, Y2, Y3, R3, R4, R5, R6, R7, R8, R9, R10, m, n and p are as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.

HETEROCYCLIC COMPOUNDS

The invention is concerned with novel heterocyclyl compounds of formula (I) wherein A, X, Y, R3, R4, R5, R6, R7, R8, R9, R10, m and n are as herein defined, as well as physiologically acceptable salts thereof. These compounds are antagonists of CCR2 receptor, CCR5 receptor and/or CCR3 receptor and can be used as medicaments.